They managed to eliminate incurable brain cancer in a 17-year-old boy using CAR-T therapy.

CAR-T therapy (Chimeric T cell antigen) is an advanced cell therapy that involves genetically modifying a patient’s immune cells, specifically T cells, to provide attack specific tumor targets. This option gives good results for blood tumors.

Now this treatment has taken an important step, showing promising results against solid tumors, especially in children with diffuse midline gliomas. A phase 1 clinical trial conducted by a team of researchers at Stanford University found significant improvements in patients with this type of brain tumor. extremely fatal, including one case of complete remission.

He Diffuse midline glioma is a primary tumor of the central nervous system. This means that it begins in the brain or spinal cord. Are malignant tumors (cancerous) and fast-growing, with a survival rate of one year after diagnosis. It occurs in children and adults, but is more common in children.

This type of tumor does not respond to chemotherapy or surgery. and radiation therapy brings only temporary relief. The study involved 11 children and young people diagnosed with diffuse midline glioma. Nine of eleven patients showed significant benefits, with improved quality of life and functional recovery.

In four cases Tumor size decreased by more than 50%and one of the patients experienced complete remission with complete disappearance of the tumor on brain images. The 17-year-old was diagnosed four years ago. He is healthy, studying at university, and his motor and sensory functions have improved.

In this case, the researchers developed CAR-T cells to target a specific marker, GD2 is widely distributed in diffuse intrinsic pontine glioma (DIPG) tumor cells.